Showing 5 posts of 5 posts found.


FDA rejects J&J’s treatment for rheumatoid arthritis

September 25, 2017
Sales and Marketing Johnson & Johnson, biotech, drugs, pharma, pharmaceutical, sirukumab

Perhaps unsurprisingly, after the FDA’s advisory committee had voted 12-1 against approval of Johnson & Johnson’s drug, the FDA returned …


FDA turns down Janssen’s sirukumab for rheumatoid arthritis

August 3, 2017
Sales and Marketing FDA, Janssen, drugs, life sciences, medicine, pharma, pharmaceuticals, rheumatoid arthritis, sirukumab

Janssen has announced that it has suffered a knockback to its plans to commercialise sirukumab in the US in the …


GSK/J&J release how their drug measures up against Humira

November 18, 2016
Medical Communications, Research and Development GSK, Humira, Janssen, Johnson & Johnson, sirukumab

GlaxoSmithKline and Janssen, part of Johnson & Johnson, released the results of their two Phase III trials exploring treatment options …


GSK and J&J file rheumatoid arthritis treatment sirukumab in EU

September 13, 2016
Manufacturing and Production, Sales and Marketing GSK, GlaxoSmithKline, Johnson & Johnson, rheumatoid arthritis, sarilumab, sirukumab

GlaxoSmithKline and partner Johnson & Johnson’s Janssen Biologics unit have filed for approval of rheumatoid arthritis (RA) treatment sirukumab in …


GSK, Janssen RA treatment meets co-primary endpoints in Phase III trial

June 9, 2016
Research and Development GSK, Janssen, eular 2016, rheumatoid arthritis, sirukumab

GSK (LSE: GSK) and Janssen, a division of Johnson and Johnson, have announced data from a pivotal Phase III study …

Latest content